IL2 and neoplasm: It was reported in 2014 that metformin suppresses tumor progression due to its activity on the AMP kinase enzyme system, and it was found that it can alter the levels of immune cells, interleukins (ILs), and cytokines such as CD8+, interleukin-2 (IL-2), tissue necrosis factor-α (TNF-α), and interferon gamma (INF-ɣ) [5].